Company Description
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus.
In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases.
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Aoife Brennan |
Contact Details
Address: 20 William Street, Suite G50 Wellesley Hills, Massachusetts 02481 United States | |
| Phone | 866 857 2596 |
| Website | climbbio.com |
Stock Details
| Ticker Symbol | CLYM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.50 |
| CIK Code | 1768446 |
| CUSIP Number | 28658R106 |
| ISIN Number | US28658R1068 |
| Employer ID | 83-2273741 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President and Director |
| Dr. Susan Altschuller M.B.A., Ph.D. | Chief Financial Officer and Principal Accounting Officer |
| Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer |
| Adam Villa | Senior Vice President of Technical Operations |
| Chandra Adams J.D. | Senior Vice President, General Counsel and Secretary |
| Ashley Jones | Senior Vice President of People and Workforce Strategy |
| Dr. Edgar D. Charles M.D., M.Sc. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 9, 2026 | SCHEDULE 13D/A | Filing |
| Nov 5, 2026 | SCHEDULE 13G/A | Filing |
| Nov 5, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Nov 5, 2026 | 10-Q | Quarterly Report |
| Nov 5, 2026 | 8-K | Current Report |
| Oct 28, 2026 | SCHEDULE 13G | Filing |
| Oct 27, 2026 | SCHEDULE 13G | Filing |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 23, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 144 | Filing |